After finishing at $8.22 in the prior trading day, BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) closed at $7.99, down -2.80%. In other words, the price has decreased by -$0.23 from its previous closing price. On the day, 2346956 shares were traded. BCRX stock price reached its highest trading level at $8.21 during the session, while it also had its lowest trading level at $7.91.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Our goal is to gain a better understanding of BCRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.40 and its Current Ratio is at 5.80.
Upgrades & Downgrades
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 03 when Thackray Helen M. sold 7,000 shares for $8.29 per share. The transaction valued at 58,030 led to the insider holds 207,275 shares of the business.
Stonehouse Jon P sold 100,000 shares of BCRX for $1,038,000 on Feb 01. The President & CEO now owns 1,008,739 shares after completing the transaction at $10.38 per share. On Dec 15, another insider, Stonehouse Jon P, who serves as the President & CEO of the company, sold 14,100 shares for $10.90 each. As a result, the insider received 153,690 and left with 887,730 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1.39B and an Enterprise Value of 1.71B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.17. Its current Enterprise Value per Revenue stands at 5.90 whereas that against EBITDA is -14.19.
Stock Price History:
Over the past 52 weeks, BCRX has reached a high of $15.43, while it has fallen to a 52-week low of $7.20. The 50-Day Moving Average of the stock is 8.19, while the 200-Day Moving Average is calculated to be 11.00.
The stock has traded on average 2.90M shares per day over the past 3-months and 2.48M shares per day over the last 10 days, according to various share statistics. A total of 188.51M shares are outstanding, with a floating share count of 184.56M. Insiders hold about 0.80% of the company’s shares, while institutions hold 81.10% stake in the company. Shares short for BCRX as of Apr 27, 2023 were 31.2M with a Short Ratio of 32.30M, compared to 31.22M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 16.52% and a Short% of Float of 18.56%.
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.3, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.12 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.67 and -$1.29 for the fiscal current year, implying an average EPS of -$0.95. EPS for the following year is -$0.54, with 10 analysts recommending between -$0.12 and -$1.18.
8 analysts predict $81.96M in revenue for the current quarter. It ranges from a high estimate of $84.13M to a low estimate of $79.65M. As of the current estimate, BioCryst Pharmaceuticals Inc.’s year-ago sales were $65.53M, an estimated increase of 25.10% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $85.97M, an increase of 15.20% less than the figure of $25.10% in the same quarter last year. There is a high estimate of $88.46M for the next quarter, whereas the lowest estimate is $84.53M.
A total of 9 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $333.97M, while the lowest revenue estimate was $323M, resulting in an average revenue estimate of $326.95M. In the same quarter a year ago, actual revenue was $270.83M, up 20.70% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $406.29M in the next fiscal year. The high estimate is $435.4M and the low estimate is $330M. The average revenue growth estimate for next year is up 24.30% from the average revenue estimate for this year.